"Dexamethasone" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
An anti-inflammatory 9-fluoro-glucocorticoid.
| Descriptor ID |
D003907
|
| MeSH Number(s) |
D04.210.500.745.432.769.344 D04.210.500.908.238
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Dexamethasone".
Below are MeSH descriptors whose meaning is more specific than "Dexamethasone".
This graph shows the total number of publications written about "Dexamethasone" by people in this website by year, and whether "Dexamethasone" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1995 | 4 | 0 | 4 |
| 1996 | 1 | 0 | 1 |
| 1997 | 0 | 1 | 1 |
| 1998 | 2 | 0 | 2 |
| 1999 | 3 | 4 | 7 |
| 2000 | 3 | 0 | 3 |
| 2001 | 0 | 2 | 2 |
| 2002 | 1 | 6 | 7 |
| 2003 | 1 | 7 | 8 |
| 2004 | 3 | 2 | 5 |
| 2005 | 2 | 4 | 6 |
| 2006 | 4 | 4 | 8 |
| 2007 | 3 | 1 | 4 |
| 2008 | 2 | 4 | 6 |
| 2009 | 1 | 1 | 2 |
| 2010 | 4 | 1 | 5 |
| 2011 | 2 | 4 | 6 |
| 2012 | 2 | 4 | 6 |
| 2013 | 3 | 2 | 5 |
| 2014 | 0 | 7 | 7 |
| 2015 | 5 | 6 | 11 |
| 2016 | 4 | 2 | 6 |
| 2017 | 2 | 3 | 5 |
| 2018 | 5 | 4 | 9 |
| 2019 | 1 | 2 | 3 |
| 2020 | 2 | 5 | 7 |
| 2021 | 1 | 9 | 10 |
| 2022 | 0 | 8 | 8 |
| 2023 | 0 | 3 | 3 |
| 2024 | 2 | 2 | 4 |
To return to the timeline,
click here.
Below are the most recent publications written about "Dexamethasone" by people in Profiles.
-
Gain-of-Function Chromatin Remodeling Activity of Oncogenic FOXL2C134W Reprograms Glucocorticoid Receptor Occupancy to Drive Granulosa Cell Tumors. Cancer Res. 2025 Mar 03; 85(5):875-893.
-
Daratumumab plus lenalidomide/dexamethasone in untreated multiple myeloma: analysis of key subgroups of the MAIA study. Leukemia. 2025 Mar; 39(3):710-719.
-
Physical Activity and Dexamethasone for Cancer-Related Fatigue: A Preliminary Placebo-Controlled, Randomized, Double-Blind Trial. J Natl Compr Canc Netw. 2025 01 07; 23(1).
-
Hyper-CVAD and Sequential Blinatumomab Without and With Inotuzumab in Young Adults With Newly Diagnosed Philadelphia Chromosome-Negative B-Cell Acute Lymphoblastic Leukemia. Am J Hematol. 2025 Mar; 100(3):402-407.
-
Dexamethasone dose intensity does not impact outcomes in newly diagnosed multiple myeloma: a secondary SWOG analysis. Blood. 2025 Jan 02; 145(1):75-84.
-
An inflammatory state defines a high-risk T-lineage acute lymphoblastic leukemia subgroup. Sci Transl Med. 2025 Jan; 17(779):eadr2012.
-
Outcomes of Standard-Risk Multiple Myeloma Patients Who Undergo Upfront Autologous Hematopoietic Stem Cell Transplantation. Transplant Cell Ther. 2025 Mar; 31(3):166.e1-166.e9.
-
Longitudinal follow up of a phase 2 trial of venetoclax added to hyper-CVAD, nelarabine and pegylated asparaginase in patients with T-cell acute lymphoblastic leukemia and lymphoma. Leukemia. 2024 Dec; 38(12):2717-2721.
-
IT-DEX and B cell depletion in a child with anti-GAD 65 autoimmune encephalitis presenting as NORSE: A case report. J Neuroimmunol. 2024 10 15; 395:578430.
-
Daratumumab in transplant-eligible patients with newly diagnosed multiple myeloma: final analysis of clinically relevant subgroups in GRIFFIN. Blood Cancer J. 2024 07 08; 14(1):107.